| 40.12 Delayed Data As of Jun 14 |  -0.01 / -0.02%Today’s Change | 36.41 Today|||52-Week Range 42.32 | +5.00% Year-to-Date |
| Glaxo Inks Genome Research Deal With University of California Jun 14 / Zacks.comZAK - Paid Partner Content | Better Buy: GlaxoSmithKline vs. Merck Jun 06 / MotleyFool.comFOO - Paid Partner Content |
| Christopher Browne: Finding Value Away From Home Jun 12 / GuruFocus NewsGURU - Paid Partner Content | Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options Jun 05 / Zacks.comZAK - Paid Partner Content |
| 6 Guru Stocks With Low Price-Sales Ratios Jun 11 / GuruFocus NewsGURU - Paid Partner Content | Emergent (EBS) Wins HHS Contract to Supply VIGIV Product Jun 04 / Zacks.comZAK - Paid Partner Content |
| Is Gilead Sciences Worth the Wait? Jun 09 / MotleyFool.comFOO - Paid Partner Content | Matinas BioPharma to Present at the 9th Annual LD Micro Invitational Jun 03 / GlobeNewswirePNW - Paid Partner Content |
| Previous close | 40.13 |
| Today’s open | 39.95 |
| Day’s range | 39.92 - 40.15 |
| Volume | 1,836,589 |
| Average volume (3 months) | 2,498,224 |
| Market cap | $100.0B |
| Earnings growth (last year) | +143.10% |
| Earnings growth (this year) | -8.05% |
| Earnings growth (next 5 years) | +3.85% |
| Revenue growth (last year) | +5.72% |
| P/E ratio | 20.3 |
| Price/Sales | 2.31 |
| Price/Book | 17.78 |
| Today’s change | Today’s % change | |
|---|---|---|
| AZNAstraZeneca | -0.24 | -0.60% |
| SNYSanofi | -0.21 | -0.49% |
| NVONovo Nordisk | -0.74 | -1.43% |
| LLYEli Lilly and Co | -0.08 | -0.07% |
| Next reporting date | July 24, 2019 |
| EPS forecast (this quarter) | $0.64 |
| Annual revenue (last year) | $41.1B |
| Annual profit (last year) | $4.8B |
| Net profit margin | 11.75% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Executive Director Emma Walmsley |
Chief Financial Officer & Executive Director Iain James Mackay |
Corporate headquarters Brentford, Greater London |
